View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with Oximio
  1. Sponsored
April 19, 2021updated 20 Apr 2021 9:07am

The SMO Group announces company name change to Oximio

The global clinical trial services provider The SMO Group announced earlier this year that the company will begin operating under a new name and will be known henceforth as Oximio, effective immediately. The 18-month extensive rebranding project is a response to the accelerated company growth and a renewal of the company vision.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

“By announcing Oximio, we are opening the next chapter in the company’s history. In the past 16 years we have grown to become a truly global company, constantly focusing on further geographical expansion and strengthening our service portfolio. In the past years we put a huge effort into developing a quality led organization, which has resulted in higher patient satisfaction and a wider service coverage.

“I believe it was appropriate to rebrand our company to better reflect the fresh and professional mindset of our people and to emphasize the knowledge, expertise and added value we bring to the clinical research market.” – CEO, Krisztina Varga stated. “The new brand will help us seize the opportunity to reinforce our reputation of being a well-established clinical trials services provider, building on our history and our strong company culture. We aim to provide a full brand experience to our clients to help them be more successful in their core business.

We will be working extremely hard to achieve our vision: We are dedicated to expediting research to find effective treatments and cures for all living beings.”

The company’s ownership, staff, and legal entity names remain unchanged. Both names – SMO GROUP® and OXIMIO®, as our registered trademarks will be used within a transition period and thereafter on per case basis.

For more information about the brand change, please visit our new website: oximio.com.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU